Small caps

Cash and dilution

For companies with a public float under $300M, or under $2B with the size chip: cash runway from each 10-Q and 10-K, and the public float from each annual report cover, as stated in the filings.

Biotech and pharma companies with a public float from $5M to $300M

Shortest runway first. Rows more than 60 days past their run-out date sit below, marked figures out of date. Ties: fewer days of cash, then an open listing notice, then an at-the-market offering in the last 12 months.

CompanyRunway, cash and burnFloatShares, 12 monthsLatest report
bioAffinity TechnologiesBIAFBiotech research
2 monthsRaised since report$2.4M cash$3.2M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Nov 3, 2026 424B5
$22.6Mas of Jun 30, 2025float may be out of date+553%after a reverse split
Outlook TherapeuticsOTLKBiotech
2 monthsRaised since report$11.2M cash$14.4M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-K due Dec 29, 2026. Raised since: Aug 14, 2026 424B5
$26.9Mas of Mar 31, 2025float may be out of date+270%
PluriPLURBiotech
2 monthsRaised since report$3.5M cash$4.5M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Oct 30, 2026 8-K
$15.2Mas of Dec 31, 2025+54%
Jupiter NeurosciencesJUNSPharma
2 monthsRaised since report$1.5M cash$1.9M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Aug 24, 2026 424B5
$20.2Mas of Jun 30, 2025+26%
GeoVax LabsGOVXPharma
2 monthsRaised since report$3.1M cash$3.6M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Oct 27, 2026 8-K
$13.7Mas of Jun 30, 2025float may be out of date+643%after a reverse split
Cue BiopharmaCUEPharma
2 months$17.4M cash$20.0M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 4 8-Ks since not read yet
$52.0Mas of Jun 30, 2025+99%
Cocrystal PharmaCOCPPharma
2 months$2.2M cash$2.4M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 5 8-Ks since not read yet
$11.6Mas of Jun 30, 2025+36%
Cadrenal TherapeuticsCVKDPharma
2 months$2.4M cash$2.6M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 7 8-Ks since not read yet; 1 read, not a raise
$24.9Mas of Jun 30, 2025+49%
FibroBiologicsFBLGPharma
2 months$3.5M cash$3.8M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 5 8-Ks since not read yet; 1 read, not a raise
$21.6Mas of Jun 30, 2025float may be out of date+225%
Actuate TherapeuticsACTUPharma
2 monthsRaised since report$4.4M cash$4.7M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Oct 28, 2026 8-K
$42.1Mas of Jun 30, 2025+22%
Calidi BiotherapeuticsCLDIBiotech
3 monthsRaised since report$4.1M cash$4.2M burn a quarteras of Jun 30, 2026Cash would have lasted to Sep 2026; next 10-Q due Nov 16, 2026. Raised since: Sep 17, 2026 424B5
$8.0Mas of Jun 30, 2025float may be out of date+687%may include a split or new class
AEON BiopharmaAEONPharma
3 monthsRaised since report$3.4M cash$3.2M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. Raised since: Nov 3, 2026 424B3 $29.6M
$8.7Mas of Jun 30, 2025float may be out of date+356%may include a split or new class
Moleculin BiotechMBRXPharma
3 monthsRaised since report$7.3M cash$6.4M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. Raised since: Aug 21, 2026 424B5
$8.8Mas of Dec 31, 2025float may be out of date+815%may include a split or new class
Lunai BioworksLNAIPharma
3 months$1.7M cash$1.4M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. No raise filed since Jun 30, 2026; 2 8-Ks since, neither a raise
$21.3Mas of Dec 31, 2025+63%
3 months$11.2M cash$9.2M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 1 8-K since not read yet
$27.3Mas of Jun 30, 2025float may be out of date+125%
Annovis BioANVSPharma
3 months$18.7M cash$15.5M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 3 8-Ks since not read yet; 1 read, not a raise
$36.1Mas of Jun 30, 2025+93%
Aligos TherapeuticsALGSBiotech
3 months$30.4M cash$24.0M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 2 8-Ks since not read yet
$19.9Mas of Jun 30, 2025+1%
Skye BioscienceSKYEPharma
3 months$10.1M cash$7.8M burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. No 424B or S-1 filed since Jun 30, 2026; 5 8-Ks since not read yet
$130Mas of Jun 30, 20250%
Adaptin BioAPTNBiotech
3 months$670K cash$523K burn a quarteras of Jun 30, 2026Cash would have lasted to Oct 2026; next 10-Q due Nov 16, 2026. S-1 filed since: Aug 28, 2026, new shares or resale not read yet; 1 8-K since not read yet
$9.3Mas of Jun 30, 2025+5%
BioXcel TherapeuticsBTAIQPharma
4 months$12.8M cash$9.0M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 7 8-Ks since not read yet; 1 read, not a raise
$11.0Mas of Jun 30, 2025float may be out of date+286%
Revium Rx.RVRCPharma
4 months$842K cash$584K burn a quarteras of Jun 30, 2026No raise filed since Jun 30, 2026
$14.3Mas of Jun 30, 20250%
NanoviricidesNNVCPharma
4 monthsRaised since report$2.8M cash$1.9M burn a quarteras of Jun 30, 2026Raised since: Oct 21, 2026 424B5
$23.7Mas of Dec 31, 2025+34%
Aptevo TherapeuticsAPVOPharma
4 monthsRaised since report$9.8M cash$6.7M burn a quarteras of Jun 30, 2026Raised since: Oct 30, 2026 424B5
$9.8Mas of Jun 30, 2025float may be out of date+2817%after a reverse split
Gossamer BioGOSSPharma
4 months$57.0M cash$39.1M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 12 8-Ks since not read yet; 1 read, not a raise
$271Mas of Jun 28, 2025+45%
GT BiopharmaGTBPPharma
4 months$5.0M cash$3.4M burn a quarteras of Jun 30, 2026S-1 filed since: Oct 9, 2026, new shares or resale not read yet; 5 8-Ks since not read yet
$8.6Mas of Jun 30, 2025float may be out of date+1301%may include a split or new class
Pyxis OncologyPYXSPharma
4 monthsRaised since report$33.0M cash$22.1M burn a quarteras of Jun 30, 2026Raised since: Oct 1, 2026 424B5
$64.4Mas of Jun 30, 2025+3%
PDS BiotechnologyPDSBPharma
4 monthsRaised since report$5.6M cash$3.6M burn a quarteras of Jun 30, 2026Raised since: Jul 21, 2026 424B4
$60.1Mas of Jun 30, 2025+21%
Ernexa TherapeuticsERNAPharma
4 months$5.0M cash$3.2M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 4 8-Ks since not read yet; 1 read, not a raise
$17.5Mas of Jun 30, 2025float may be out of date+472%after a reverse split
Greenland MinesGRMLBiotech
4 monthsRaised since report$9.3M cash$5.9M burn a quarteras of Jun 30, 2026Raised since: Sep 28, 2026 424B5
$52.6Mas of Jun 30, 2025float may be out of date+273%
Adicet BioACETPharma
4 months$33.1M cash$20.7M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 4 8-Ks since not read yet
$50.5Mas of Jun 30, 2025+89%
4 months$8.4M cash$5.2M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 7 8-Ks since not read yet; 1 read, not a raise
$6.5Mas of Jun 30, 2025+15%
Dyadic InternationalDYAIBiotech
4 monthsRaised since report$3.1M cash$1.9M burn a quarteras of Jun 30, 2026Raised since: Aug 13, 2026 424B5
$24.2Mas of Jun 30, 2025+21%
NextCureNXTCPharma
5 months$20.1M cash$11.5M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 4 8-Ks since not read yet; 1 read, not a raise
$12.6Mas of Jun 30, 2025float may be out of date+124%
Coherus OncologyCHRSBiotech
5 monthsRaised since report$105M cash$60.0M burn a quarteras of Jun 30, 2026Raised since: Aug 28, 2026 424B5
$81.9Mas of Jun 30, 2025+33%
ProkidneyPROKBiotech
5 monthsRaised since report$74.9M cash$41.0M burn a quarteras of Jun 30, 2026Raised since: Oct 29, 2026 8-K
$58.9Mas of Jun 30, 2025
BeyondSpringBYSIPharma
5 monthsRaised since report$6.5M cash$3.5M burn a quarteras of Jun 30, 2026Raised since: Sep 29, 2026 424B5
$69.7Mas of Jun 30, 2025+2%
Instil BioTILBiotech
5 months$5.5M cash$3.0M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 1 8-K since not read yet
$83.4Mas of Jun 30, 2025+3%
5 monthsRaised since report$36.7M cash$19.8M burn a quarteras of Jun 30, 2026Raised since: Jul 30, 2026 424B5
$74.3Mas of Jun 30, 2025float may be out of date+110%
BiovieBIVIPharma
5 monthsRaised since report$9.0M cash$4.8M burn a quarteras of Jun 30, 2026Raised since: Sep 14, 2026 424B5
$8.5Mas of Dec 31, 2025float may be out of date+391%may include a split or new class
Medicus PharmaMDCXPharma
5 months$15.2M cash$8.0M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 3 8-Ks since not read yet; 3 read, none a raise
$28.3Mas of Jun 30, 2025float may be out of date+285%
ImunonIMNNPharma
6 months$6.9M cash$3.5M burn a quarteras of Jun 30, 2026S-1 filed since: Oct 27, 2026, new shares or resale not read yet; 3 8-Ks since not read yet; 2 read, neither a raise
$21.2Mas of Jun 30, 2025float may be out of date+310%may include a split or new class
6 months$31.5M cash$16.0M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 3 8-Ks since not read yet
$40.4Mas of Jun 30, 2025+13%
PulmatrixPULMPharma
6 months$2.2M cash$1.1M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 1 8-K since not read yet; 1 read, not a raise
$25.2Mas of Jun 30, 20250%
LongeveronLGVNPharma
6 months$10.1M cash$5.0M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 9 8-Ks since not read yet; 2 read, neither a raise
$16.5Mas of Jun 30, 2025float may be out of date+109%
Liminatus PharmaLIMNBiotech
6 monthsRaised since report$3.0M cash$1.5M burn a quarteras of Jun 30, 2026Raised since: Nov 3, 2026 8-K
$221Mas of Jun 30, 2025float may be out of date+108%
Dare BioscienceDAREPharma
6 monthsRaised since report$12.6M cash$6.1M burn a quarteras of Jun 30, 2026Raised since: Aug 17, 2026 424B5
$21.3Mas of Jun 30, 2025+68%
Tvardi TherapeuticsTVRDPharma
6 monthsRaised since report$15.8M cash$7.5M burn a quarteras of Jun 30, 2026Raised since: Jul 17, 2026 424B5
$207Mas of Jun 30, 2025+11%
6 months$17.8M cash$8.5M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 2 8-Ks since not read yet
$32.4Mas of Jun 30, 2025+15%
Passage BIOPASGBiotech
6 months$24.2M cash$11.1M burn a quarteras of Jun 30, 2026No 424B or S-1 filed since Jun 30, 2026; 1 8-K since not read yet
$25.4Mas of Jun 30, 2025+1%
Lantern PharmaLTRNPharma
6 monthsRaised since report$7.4M cash$3.4M burn a quarteras of Jun 30, 2026Raised since: Sep 30, 2026 424B5
$33.9Mas of Jun 30, 2025+15%

Float may be out of date: from a fiscal year more than one year before the latest report, or followed by a share change of more than 100%.

Not ranked: 31 companies, with the reason

Operating cash flow for the last two quarters is not tagged, so there is no runway estimate. 13
Cash is not tagged in the latest report, so there is no runway estimate. 10
Cash was under 5% of total assets at the end of the period: most of the company's money is held as something other than cash, such as crypto, securities or investments not tagged as short-term, so there is no runway estimate. 4
Runway is not meaningful for blank-check companies (SPACs), which hold their cash in trust. 3
The latest report is older than 9 months, so there is no runway estimate. 1
How these figures are worked out
Runway
Cash and short-term investments over the average operating cash burn of the last two quarters, from the XBRL in the latest 10-Q or 10-K, dated by that report's balance sheet. The bar is red under 3 months, amber from 3 to 12 and grey above; the words carry the same meaning. 'Raised since report' marks a raise filed after that report: the newest 424B prospectus (a 424B3 or 424B7 only when read as a sale of new shares), an S-1 read as new shares, or an 8-K reporting an unregistered share sale (item 3.02) or a financing agreement (item 1.01). Hover the runway, or read it with a screen reader, for the detail: when the estimated run-out date has passed, the month the cash lasted to and when the next report is due; under 4 quarters, whether a raise was filed since, or how many 8-Ks since are not read yet. Rows more than 60 days past their run-out month sit below current ones, marked figures out of date.
Burn a quarter
That two-quarter average, the same figure as the runway card on each company page. When a report tags only year-to-date totals, each quarter is the longer total less the earlier one.
Not a cash-burn company
Revenue in the latest quarter was above the cash outflow, so the outflow is a swing in inventory, receivables or payables rather than a burn rate; or operating cash flow over the last four quarters or the last fiscal year was positive. These companies get no runway and are not listed here; each company page says why.
Not ranked
Banks and lenders, insurers, brokers, funds, REITs and other real estate companies, partnerships and SPACs (SIC 6770, or a name with 'Acquisition Corp', or with 'Acquisition' and under 5% of assets in cash because the rest is in trust), companies with no tagged cash, a latest 10-Q or 10-K more than 9 months old, and figures that fail a check (cash and cash flow from different periods, cash above total assets, or under a week of cash while cash is under 5% of assets). They are listed under 'Not ranked' below the table, grouped by the reason.
Shares, 12 months
Change in diluted shares against the same quarter a year earlier, split-adjusted as the latest report restates them. A change above +300% or below −40% reads 'after a reverse split' when we found one ('reverse split adjusted'), and otherwise 'may include a split or new class' ('share count may include a split or a new class; check the source'), linked to the report.
Float
The public float on the cover of the latest annual report, as of the end of the second fiscal quarter, linked to EDGAR; hover it for its date. 'Float not stated' replaces $0, or a float over 1,000 times cash that neither the last offering price nor 100 times total assets supports. A float from a fiscal year more than one year before the latest report's, or followed by a share change of more than 100%, is marked with a dot, 'float may be out of date'.
Shells
By default a company with no stated public float, or under $25K of cash, is a shell or near-shell, and is hidden; turn off 'Hide shells' to list them.
Sector
The SIC code on file with the SEC, corrected for a few companies whose code does not match their business. Filters combine: each one narrows the list.

An estimate from reported figures, not a forecast or advice.

Small-cap signals read from every filing

  1. Cash runway

    Months of cash at the latest burn, from each 10-Q and 10-K.

    XBRL: cash, securities, operating cash flow

  2. Going-concern status

    Companies whose latest report carries a going-concern warning the prior one did not.

    10-Q and 10-K text, auditor report

    None in 30 days
  3. Dilution ladder

    Shares outstanding over time on each company's dilution page; shelf, ATM, warrants and convertibles are not read yet.

    S-3, 424B, 8-K item 1.01, notes

  4. Offerings with the math

    Priced offerings, at-the-market programs and shelf takedowns, with new shares and the discount.

    424B, S-3, 8-K

    70 in 30 days
  5. Toxic financing flags

    Discounted conversion prices, warrant resets, ratchets and equity lines, with the clause quoted.

    Exhibits 4 and 10

    5 in the 30 days to Nov 2
  6. Listing compliance

    Open Nasdaq and NYSE deficiency notices, the rule and the cure deadline.

    8-K item 3.01

    199 open listing notices
  7. Audit risk

    Auditor changes, restatements and late filings.

    8-K items 4.01 and 4.02, NT filings

    Late filings: 24, Auditor changes: 11, Restatements: 4 in 30 days
  8. Insider cluster buys

    Three or more officers or directors buying the same company on the open market within 30 days, $25K or more in all.

    Form 4

    1 last 30 days, under $300M float

Figures as reported in each filing. Not investment advice. Not affiliated with the U.S. SEC. All screens